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Introduction:Abnormal retinal changes are increasingly recognized as an early patho-
logical change inAlzheimer’s disease (AD). Althoughamyloid betaoligomers (Aβo) have
been shown to accumulate in the blood and retina of AD patients and animals, it is not
knownwhether the early Aβo deposition precedes their accumulation in brain.
Methods and results:Using nanobodies targeting Aβ1-40 andAβ1-42 oligomerswewere
able to detect Aβ oligomers in the retina and blood but not in the brain of 3-month-old
APP/PS1 mice. Furthermore, Aβ plaques were detected in the brain but not the retina
of 3-month-old APP/PS1mice.
Conclusion: These results suggest that retinal accumulation of Aβo originates from
peripheral blood and precedes cognitive decline and Aβo deposition in the brain. This
provides a very strong basis to develop and implement an “eye test” for early detection
of AD using nanobodies targeting retinal Aβ.
KEYWORDS
amyloid beta oligomers, Alzheimer’s disease, APP/PS1 mice, blood immunodetection, early
Alzheimer’s disease diagnosis, nanobodies, retinal immunodetection
1 INTRODUCTION
The importance of amyloid beta oligomer (Aβo) detection has gained
momentum and experimental studies using humanAlzheimer’s disease
(AD) samples have shown that this form can be detected as much as
twodecadesbefore clinical onset ofAD.1–4 Aβocanpotentially become
a strong biomarker for early AD detection and could provide accurate
biochemical information about various preclinical stages of AD. Sev-
eral investigators have shown experimentally that blood-borne Aβo is
a viable biomarker for human AD. A study by Nakamura et al.5 has
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
© 2021 The Authors. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring published byWiley Periodicals, LLC on behalf of Alzheimer’s Association
identified high-performance plasma Aβ biomarkers using a combina-
tion of immunoprecipitation and mass spectrometry and suggested
that plasma Aβ ratio can predict brain Aβ burden. Plasma Aβ precursor
protein (APP)669–711/Aβ1–42 and Aβ1–40/Aβ1–42 were correlated with
brain Aβ levels determined by Aβ positron emission tomography (PET)
imaging.
Ocular disturbances are an early complaint in AD patients6–8 with
reported changes in color vision, contrast sensitivity, visual memory
and perception,9–11 nerve damage, and loss of nerve fibers.12 Gan-
glion cell loss13 and thinning of the retinal nerve fiber layer (RNFL)14,15
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have also been reported. A recent study by Coppola et al.16 reported
that RNFL thinning was associated with neurodegenerative progres-
sions in mild cognitive impaired (MCI) and AD patients compared to
cognitively healthy individuals. Similar color vision and contrast sen-
sitivity deficits were shown in a murine model of AD. In addition
to neuronal changes in the retina, alteration of retinal blood flow
and morphology has also been noted.17 Importantly, Aβ deposits in
the retina of AD patients were identified by histology18 and in vivo
imaging of MCI and AD patients.19 Subsequent studies have corrobo-
rated these findings and showed accumulation of Aβ and hyperphos-
phorylated tau (p-tau) in the retina of AD patients20–22 and animal
models.23
Nanobodies are camelid-derived antibody fragments with unique
biological features, including lack of light chains, smaller size (more
diffusible in tissues), hydrophilic (soluble in aqueous solution), highly
stable, and more resistant against chemical denaturation.24 Previous
studies reported that nanobodies targeting Aβ and neurofibrillary tan-
gles inmice brain parenchyma are able to cross the blood-brain barrier
(BBB).25 Another study demonstrated that nanobodies specific for Aβ
oligomers prevent neurotoxicity and fibril formation.26 Moreover, Van-
desquille et al. showed that nanobodies were able to detect cerebral
Aβ plaque deposits via magnetic resonance imaging (MRI) after intra-
venous injection.27
In the current study, we used nanobody anti-Aβ1-40 (PrioAD12)
and anti-Aβ1-42 (PrioAD13) oligomer antibodies28 to measure the lev-
els of Aβo in the brain and retina of the APP/PS1 mice25 at 3 to
4 months of age with immunohistochemistry (IHC), before behav-
ioral changes and appearance of cognitive deficits. We showed that
retinal Aβ1-40 and Aβ1-42 oligomer levels were significantly higher in
APP/PS1 mice compared to age-matched WT controls. Furthermore,
immunofluorescence (FL) analysis confirmed our IHC results and sur-
prisingly resulted in the detection of large amounts of Aβo in the 18-
month-old APP/PS1 age group. We also confirmed the localization of
both Aβ1-40 and Aβ1-42 oligomers to neuronal late-endosomal com-
partments in the retina and brain29 that was associated with acti-
vated astrocytes andmicroglia in APP/PS1mice. Of importance, Aβ1-40
and Aβ1-42 levels in whole blood quantified by western blotting with
the nanobodies were elevated in 3- and 18-month-old APP/PS1 mice
compared to wild-type (WT) controls. The observation that Aβo was
detectable in the retina and blood but not in the brain of young
APP/PS1 mice suggests that deposition of retinal Aβo might origi-
nate from the blood. Taken together, our results provide an important
milestone in achieving an “eye” and/or blood-based screening test for
AD.
2 METHODS
2.1 Animals and ethics statement
All procedures followed the requirements of the National Health and
Medical Research Council of Australia statement for the use of ani-
mals in research andwere approved by theWestern SydneyUniversity
RESEARCH INCONTEXT
1. Systematic review: Although several experimental stud-
ies have demonstrated the presence of blood-borne
amyloid beta oligomers (Aβo) decades before clini-
cal Alzheimer’s disease (AD) and neuropathology have
ensued, few studies have focused on the early detection
of Aβ oligomers in the retina and other eye structures.
2. Interpretation: The results of this study involving the
double-transgenic APP/PS1 AD mouse model showed
that Aβo could be detected simultaneously in blood and
retina before its deposition in the brain and appearance
of cognitive decline.
3. Future directions: Future research in this field should aim
to establish a routine clinical optical retinal and/or blood-
based test for the detection of human AD before cogni-
tive decline and neuropathology have ensued. The ability
to detect AD before clinical disease will potentially facili-
tate implementation of effective therapies.
Animal Ethics Committee (ACEC # A12905). Mice were housed with
free access to water and standard rodent chow (Gordon’s Specialty
Stock Feeds). APP/PS1 mice have the APP Swedish mutation K595N
andM596L30 and PSEN1with L166Pmutation controlled by the Thy1
promoter (ww.alzforum.org). Cognitive impairment is usually observed
after 7 months.31,32 The APP/PS1 mouse model has high brain levels
of Aβ1-42 over Aβ1-40, which increases with age.33,34 Age-matchedWT
littermates were used as a control.
2.2 Immunohistochemistry
APP/PS1 mice (n = 28) and WT littermates (n = 20) were first eutha-
nized (Advanced Anesthesia Specialists, DarvallVet) before perfusion
with saline followed with 10% neutral buffered formalin. Formalin
fixed paraffin embedded blocks (FFPE) were prepared using 10%
neutral buffered formalin as a fixative followed by graded ethanol
and xylene. 6μm thick brain and eye tissue sections were cut using a
microtome (Thermo Fisher Scientific). Sections were then deparaf-
finized with xylene and rehydrated through graded alcohols and finally
washedwith deionized water.
Sections were pretreated using the 2100 antigen retriever (Aptum
Biologics Ltd) to expose the target epitopes. Sections were then
treated with 90% formic acid for 5 minutes at room temperature
followed by cell membrane permeabilization, which was achieved
by using 1% triton X for 1 minute prior to addition of 0.3% H2O2
for 15 minutes to inactivate endogenous peroxidases. Sections were
then blocked with Protein Block Serum-Free (Agilent) for 15 minutes.
Sections were then stained for 1 hour with the following primary
antibodies in phosphate-buffered saline (PBS): anti-Aβ1-40 (PrioAD12),
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anti-Aβ1-42 (PrioAD13) antibodies (1:500),28 ormouse anti-Aβ purified
4G8 antibody (1:500; BioLegend). After washing with PBS, sections
were incubated for 1 hour at room temperature with secondary
antibodies in PBS:horseradish peroxidase (HRP)-conjugated anti-
llama immunoglobulin G (IgG; Bethyl Laboratories) or anti-mouse
IgG (Sigma-Aldrich). Sections were then washed in PBS (x3) before
addition of DAB substrate chromogen system and incubated for 5 to
10 minutes. Slides were then counterstained with hematoxylin for 1
minutes. The Olympus VS 120 Slide Scanner was used to visualize
images and the Olympus OlyVIA and Olympus cellSens imaging
software were used for analysis.
2.3 Immunofluorescence co-localization studies
Double immuno-labeling was achieved by two different fluores-
cent labels, each having a separate emission wavelength. Sections
were incubated overnight with anti-Aβ1-40 (PrioAD12), anti-Aβ1-42
(PrioAD13) or 4G8 antibody at 4◦C. Sections were also incubated
with camelid antibodies and mouse anti-lysosomal-associated mem-
brane protein 2 (LAMP2, Stressgen Bioreagents Corp) antibody
to assess whether Aβo localizes to lysosomes/late endosomes.
Sections derived from the 3- to 4-month-old group were incu-
bated with camelid antibodies and GFAP or Iba1 (Thermo Fisher
Scientific). Finally, sections were incubated with camelid-derived
antibodies and anti-NeuN mAb, clone A60 (MilliporeSigma) to con-
firm the intra-neuronal localization of the Aβos. All the sections
were incubated overnight at 4◦C. After washing with PBS, sec-
tions were then incubated with goat anti-llama IgG conjugated
to fluorescein isothiocyanate (FITC; Bethyl Laboratories, Inc) and
donkey-anti-mouse IgG conjugated to Texas Red (Sigma-Aldrich)
for 2 hours at 4◦C. Sections were then mounted using fluorescence
mounting media (Agilent) then visualized using an Olympus VS 120
slide scanner with a standard FITC/Texas Red double band-pass
filter set.
2.4 Image quantification
For the quantification of the age-dependent accumulation of Aβ plaque
(Aβp) and Aβo, we used three sections derived from the 3- to 4-month-
oldAPP/PS1 (n=8) andWT (n=8)mice aswell as the17- to18-month-
old APP/PS1 (n=8) andWT (n=8)mice. Three different hippocampus,
cerebral cortex, and retinal sections were analyzed. Immunohisto-
chemical signal intensitywasvisualizedby capturingbright field images
using the Olympus VS 120 slide scanner. Images were analyzed using
OlyVIA software.35,36 Age-dependent accumulation of Aβp and Aβo
in APP/PS1 mice was quantified using cellSens image processing soft-
ware. The mean intensity of particles was calculated in several brain
and retinal regions from each age group and the result was presented
as percentage intensity and expressed asmean± standard error of the
mean.
2.5 Immunoprecipitation and western blot
analysis of Aβo in whole blood
To measure blood levels of Aβo in APP/PS1 mice, we performed
immunoprecipitation to enrich/isolate Aβ from 3 to 4- and 17 to
18-month-old mice as described.37 Samples were loaded on pre-
cast gels (Bio-Rad) and electrophoresed and 1 μg/mL of nanobody
Aβ1-40 (PrioAD12), Aβ1-42 (PrioAD13) anti-oligomer antibodies28 or
A11 rabbit-anti-Aβo antibody (MilliporeSigma) was added followed by
anti-llama (Bethyl Laboratories) or anti-rabbit IgG (Sigma-Aldrich)HRP
conjugated antibody. The resulting digital images were analyzed with
ImageJ processing program for the densitometry analysis and values
between the transgenic APP/PS1 andWT controls were compared.
2.6 Statistical analyses
Statistical analyses were performed using SAS Enterprise Guide ver-
sion 8.2. A natural logarithm transformation was applied to the mea-
surements. Shapiro-Wilk test was used to determine normality. Group
differences were analyzed by Wilcoxon-Mann-Whitney test due to
non-normality. The blood-borne Aβo performance at 3 to 4 months
when predicting Aβp at 17 to 18 months in both brain and eye was not
performed because these data were not measured on the same animal
over time. There were 36 comparisons overall so a Bonferroni correc-
tion of 0.05/36 = 0.0014 was applied, meaning P-values less than this
were considered statistically significant.
3 RESULTS
3.1 Immunodetection of Aβ plaques and
oligomers in the brain and retina of APP/PS1 mice
using single-domain antibodies
In this study, we wanted to test the hypothesis that retinal Aβo accu-
mulation precedes neurobehavioral deficits but also predates brain
deposition of both Aβo and Aβp in young APP/PS1 mice using single-
domain camelid-derived anti-Aβo antibody fragments and the 4G8
anti-Aβp antibody (Table 1 andFigures 1–4).Of note, the single-domain
antibody fragments, called PrioAD12 and PrioAD13, were previously
shown to bind to Aβ1-40 and Aβ1-42, respectively.28 Here, we showed
widespread intra-neuronal Aβ1-40 and Aβ1-42 oligomers in the retinal
inner nuclear layer (INL), outer nuclear layer (ONL), and ganglion cell
layer (GCL) of the 3-month-old APP/PS1 mice (Figure 1C & F); in con-
trast, no Aβo depositions were seen in the brains at the same age (Fig-
ure 1A, B, D, E), indicating that retinal Aβo accumulation precedes
its appearance in the brain. Furthermore, no 4G8-specific Aβp was
found in the brain and retina of the 3-month-old APP/PS1 mice (Fig-
ure 1G, H, I). Interestingly, both Aβ1-40 and Aβ1-42 were detected at 8
months of age in the cerebral cortex andhippocampusofAPP/PS1mice
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TABLE 1 Age-dependent accumulation of Aβ oligomers and plaques in the blood, retina and brain of APP/PS1mice
Age groups (months) PRIOAD12 (Aβ1-40) or PRIOAD13 (Aβ1-42) 4G8 (Aβ plaques)
Blood Retinal layers Brain Retinal layers Brain
Cerebral cortex Hippocampus Cerebral cortex Hippocampus
3–4 (n= 16) Present Present Absent Absent Absent Absent Absent
8–11 (n= 16) Nd* Present Present Present Present Present Present
17–18 (n= 16) Present Absent Absent Absent Present Present Present
Abbreviations: Aβ, amyloid beta; Nd, Not determined.
F IGURE 1 Immunohistochemical staining of amyloid beta (Aβ) in the brain and retina of 3-month-old APP/PS1mice. Immunohistochemical
staining with anti-Aβ1-40 and anti-Aβ1-42 oligomer nanobodies and 4G8 anti-Aβ plaque antibody of 3-month-old APP/PS1mice.
Immunohistochemical staining with anti-Aβ1-40 (PrioAD12) and anti-Aβ1-42 (PrioAD13) nanobodies of a 3-month-old APP/PS1mice did not
demonstrate Aβ1-40 depositions in the (A) cerebral cortex and (B) hippocampus as well as Aβ1-42 depositions in the (D) cerebral cortex and (E)
hippocampus. Aβ1-40 and Aβ1-42 depositions were observed in the (C, F) ganglion cell layer (GCL), inner nuclear layer (INL), and outer nuclear layer
(ONL) of the retina. The photomicrographwas derived from peripheral region of the retina—away from the optic disc. Immunohistochemical
staining with 4G8 antibody of 3-month-old APP/PS1mice did not display characteristic extracellular Aβ plaques in the (G) hippocampus, (H)
cerebral cortex, and (I) retina. Representative of all affectedmice in this age group
(Figure 2A, B, D, E) as well as in the retina similar to 3-month-old
APP/PS1 mice (Figure 2C, F). 4G8-specific Aβp was also observed in
the cerebral cortex, hippocampus, and INL of the retina at 8 months
(Figure 2G, H, I). Both Aβo and Aβp were detectable in the cere-
bral cortex, hippocampus, and retinal layers of 11-month-old APP/PS1
mice (Figure 3A-I). Finally, no Aβo were detected in 18-month-old
APP/PS1mice (Figure 4A, B, C, D, E, F), whereas extensive, widespread,
and conspicuous Aβp was observed in the cerebral cortex, hippocam-
pus (Figure 4 G, H), and retinal INL (Figure 4 I). No Aβo or Aβp
deposits were seen in age-matched WT littermates (data not shown).
Overall our data confirm that Aβo deposits first appear in the retina
months before they are detectable in the brain and support the
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F IGURE 2 Immunohistochemical staining of amyloid beta (Aβ) in the brain and retina of 8-month-old APP/PS1mice. Immunohistochemical
staining with anti-Aβ1-40 and anti-Aβ1-42 oligomer nanobodies and 4G8 anti-Aβ plaque antibody of 8-month-old APP/PS1mice.
Immunohistochemical staining with anti-Aβ1-40 (PrioAD12) and anti-Aβ1-42 (PrioAD13) nanobodies of 8-month-old APP/PS1mice showed
presence of Aβ1-40 depositions in the (A) cerebral cortex and (B) hippocampus as well as Aβ1-42 depositions in the (D) cerebral cortex and (E)
hippocampus. Aβ1-40 and Aβ1-42 depositions were observed in the (C, F) ganglion cell layer (GCL), inner nuclear layer (INL), and outer nuclear layer
(ONL) of the retina. The photomicrographwas derived from peripheral region of the retina—away from the optic disc. Immunohistochemical
staining with 4G8 antibody of 8-month-old APP/PS1mice displayed extensive extracellular Aβ plaque staining in the (G) hippocampus, (H) cerebral
cortex, and (I) retina. Representative of all affectedmice in this age group
proposition that the retinal oligomers probably originate from the
blood.38 These results also validate our previous findings that showed
Aβp burden increased over the course of the disease in both brain and
retina, whereas Aβo levels appeared to decrease in an age-dependent
manner.39
3.2 Quantitative analysis of Aβ plaques and
oligomers in the brain, retina, and whole blood of
APP/PS1 mice using single-domain antibodies
Age-dependent retinal and brain accumulation of Aβp and Aβo in the
3- to 4-month-old APP/PS1 mice (n = 8) and WT littermates (n = 8)
was quantified and compared to Aβp and Aβo levels in the 17- to 18-
month-old APP/PS1 mice (n = 8) and WT littermates (n = 8; Tables 2
and3; Figure5). Threedifferent areasof retina, hippocampus, andcere-
bral cortex of each section (32 x 3 sections) were analyzed. Figure 5
shows the normalized intensity of retinal and brain Aβ as measured
by the cellSens image processing software and the values for Aβ1-40
(PRIOAD12antibody), Aβ1-42 (PRIOAD13antibody), and total Aβ (4G8
antibody).We found that the normalized intensity of retinal Aβ1-40 and
Aβ1-42 oligomers were significantly higher in 3- to 4-month-old com-
pared to the 17- to 18-month-old APP/PS1 mice (P = .0002; Tables 2
and 3), whereas normalized intensity of brain Aβp was significantly
higher in the retina and brain of 17- to 18-month-old compared to the
3- to 4-month-old APP/PS1mice (P= .0002; Tables 2 and 3; Figure 5).
Several studies have demonstrated the presence of Aβo in plasma
of patients with MCI and AD;5,40,41 plasma levels may also predict the
brain Aβ burden. In this study, we hypothesized that Aβo accumula-
tion in blood might also precede retinal accumulation or at least occur
simultaneously with retinal accumulation. Here, we used fresh whole
blood in blood lysis buffer to enrich Aβo. Initially and after lysingwhole
blood derived fromAPP/PS1mice, anti-oligomer-A11-coated immuno-
magnetic microbeads were used to isolate Aβ from APP/PS1 mice and
WT littermates (APP/PS1, n= 16, andWT, n= 16). After western blot-
ting, anti-Aβ1-40 (PrioAD12) or anti-Aβ1-42 (PrioAD13) oligomer single-
domain antibodies were used to immunodetect Aβo isoforms in 3- and
18-month-old APP/PS1 andWTmice. Anti-Aβ1-40 PrioAD12 displayed
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F IGURE 3 Immunohistochemical staining of amyloid beta (Aβ) in the brain and retina of 11-month-old APP/PS1mice. Immunohistochemical
staining with anti-Aβ1-40 and anti-Aβ1-42 oligomer nanobodies and 4G8 anti-Aβ plaque antibody of 11-month-old APP/PS1mice.
Immunohistochemical staining with anti-Aβ1-40 (PrioAD12) and anti-Aβ1-42 (PrioAD13) nanobodies of 11-month-old APP/PS1mice showed
presence of Aβ1-40 oligomer depositions in the (A) cerebral cortex and (B) hippocampus as well as Aβ1-42 oligomer depositions in the (D) cerebral
cortex and (E) hippocampus. Aβ1-40 and Aβ1-42 depositions were observed in the (C, F) ganglion cell layer (GCL), inner nuclear layer (INL), and outer
nuclear layer (ONL) of the retina. The photomicrographwas derived from peripheral region of the retina—away from the optic disc.
Immunohistochemical staining with 4G8 antibody of 11-month-old APP/PS1mice displayed extensive extracellular Aβ plaque staining in the
(G) hippocampus, (H) cerebral cortex, and (I) retina. Representative of all affectedmice in this age group
a two-band pattern ranging between10 and15 kDa in the 3-month-old
APP/PS1 mice, whereas only one band at 10 to 15 kDa was seen in the
18-month-old APP/PS1 age group (Figure S1A, B in supporting infor-
mation). In contrast, anti-Aβ1-42 PrioAD13 showed only one band at 10
to 15 KDa in both the 3- and 18-month-old APP/PS1 age groups (Fig-
ure S1A, B). Furthermore, we also used A11 rabbit anti-Aβo antibody
to immuno-compare Aβ1-40 and Aβ1-42 levels detected with PrioAD12
and PrioAD13. In both age groups A11 displayed a different band pat-
tern compared to the single-domain antibodies and rangedbetween70
and 80 kDa (Figure S1A, B).We then performed densitometric analysis
of scanned western blot membranes.42 Table 2 shows the normalized
intensity of whole-blood Aβ as measured by ImageJ software and the
values for Aβ1-40 (PRIOAD12 antibody) and Aβ1-42 (PRIOAD13 anti-
body). Levels of both Aβ1–40 and Aβ1–42 oligomers were not signifi-
cantly higher compared to theWT levels in the 3-month age group (P=
.0286) when a Bonferroni correction was applied. However, when the
statistical analysis was performed using paired t-tests (P-values below
.05 were deemed significant in this case) to compare levels of both
Aβ1–40 and Aβ1–42 oligomers in APP/PS1 versusWT, these were signif-
icant (P < .05; Figure 6). Levels of Aβ1-40 increased significantly from 3
to 18 months while Aβ1-42 decreased by at least three-fold in the 18-
month-old APP/PS1 mice (Figure 6). These results also highlight the
high binding affinity of the camelid-derived single domain antibodies
for detection of Aβ1-40 and Aβ1-42 oligomers in whole blood.
3.3 Co-localization of Aβ oligomers and plaques
in the retina and brain of APP/PS1 mice
TodeterminewhetherAβ1-40 orAβ1-42 oligomers co-localizedwithAβp
in different anatomical regions and structures of the retina and brain,
we co-stained brain and retinal sections with 4G8 antibody with either
anti-Aβ1-40 (PrioAD12) or anti-Aβ1-42 (PrioAD13) oligomer single-
domain antibodies (Figure 7). We did not observe any co-localization
in the brain and retina of the 3-month-old APP/PS1mice (Figure 7A-F)
but confirmed the presence of Aβ1-40 or Aβ1-42 oligomer in the reti-
nal layers (Figure 7C, F). However, both retinal Aβp and Aβ1-40 or
Aβp and Aβ1-42 were shown to co-localize in the GCL, IPL, and INL of
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F IGURE 4 Immunohistochemical staining of amyloid beta (Aβ) in the brain and retina of 18-month-old APP/PS1mice. Immunohistochemical
staining with anti-Aβ1-40 and anti-Aβ1-42 oligomer nanobodies and 4G8 anti-Aβ plaque antibody of 18-month-old APP/PS1mice.
Immunohistochemical staining with anti-Aβ1-40 (PrioAD12) and anti-Aβ1-42 (PrioAD13) nanobodies of 18-month-old APP/PS1mice did not show
presence of Aβ1-40 depositions in the (A) cerebral cortex and (B) hippocampus as well as Aβ1-42 in the (D) cerebral cortex and (E) hippocampus.
Aβ1-40 and Aβ1-42 depositions were not observed (C, F) in the ganglion cell layer (GCL), inner nuclear layer (INL), and outer nuclear layer (ONL) of
the retina. The photomicrographwas derived from peripheral region of the retina—away from the optic disc. Immunohistochemical staining with
4G8 antibody of 18-month-old APP/PS1mice displayed extensive extracellular Aβ plaque staining in the (G) hippocampus and (H) cerebral cortex
and (I) plaques were observed in the retina (white arrows). Representative of all affectedmice in this age group
the 8-month-old APP/PS1 age group (Figure 7I, L). Furthermore, co-
accumulation of Aβp and Aβ1-40 or Aβp and Aβ1-42 was also seen in
the cerebral cortex and hippocampus (Figure 7G, H, J, K), noticeably
higher levels of Aβo in this age group compared to plaques. Aβp in
11-month-old APP/PS1mice wasmarkedly increased while Aβ1-40 and
Aβ1-42 oligomers decreased in the brain (Figure 7M, N, P, Q). High lev-
els of Aβ1-40 andAβ1-42 oligomerswere consistently found in the retina
(Figure 7O, R). Finally, 18-month-old APP/PS1 mice showed that both
Aβ1-40 and Aβ1-42 co-localized with Aβp in the cerebral cortex and hip-
pocampus and in the retinal GCL, INL, and ONL (Figure 7S-X). Surpris-
ingly, high levels of Aβ1-40 and Aβ1-42 oligomers were observed in the
retina and brain of 18-month-old APP/PS1mice (Figure 7S-X), perhaps
confirming the hypothesis that plaques act as a reservoir for the toxic
Aβo.43 WTage-matched littermates did not showany co-localizationof
Aβpwith Aβ1-40 or Aβ1-42 (data not shown).
4 DISCUSSION
Behavioral assessment of theAPP/PS1ADmousemodel demonstrated
that memory decline and cognitive deficits start after 7 months of
age.32 Althoughour studydidnot includebehavioral assessments,mice
appeared healthy until 10months of age. Of importance, we show that
increased Aβo in blood and retinal accumulation of Aβo was observed
at 3 months in APP/PS1 mice in the absence of Aβp accumulation
in the retina and before appearance of both Aβo and Aβp in brain.
The accumulation of blood and retinal Aβo occur at a very early age,
likely months before the expected memory and cognitive deficits in
APP/PS1 mice. These data indicate that these assemblies are likely to
be responsible for the toxic effects associated with AD,44,45 can be
detected before AD onset,46 and might originate from the blood.38
Several diagnostic strategies have been developed for early AD detec-
tion, including systems for the detection of Aβo in plasma40 and in
the cerebrospinal fluid (CSF).47 The experimental value of detecting
blood-borne Aβ biomarkers has gained considerable momentum;48,49
however, a decade of research efforts in this area has not yet led to
a clinical diagnostic due to the complexity and lack of reproducibil-
ity of these approaches.50 Nonetheless, pursuing a blood-detection
approach might have great diagnostic value.51 A recent study combin-
ing immunoprecipitation and mass spectrometry led to the identifica-
tion of high-performance blood-borne Aβs derived from human MCI
and AD.5 Similarly, using our unique camelid single-domain anti-Aβ1-40
or anti-Aβ1-42 oligomer antibody, we were able to detect both Aβ1-40
and Aβ1-42 oligomer in whole blood derived from 3- to 18-month-old
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TABLE 3 Age-dependent retinal and brain accumulation of Aβp
and Aβo in the 3- to 4-month-old APP/PS1mice were quantified and
compared to Aβp and Aβo levels in the 17- to 18-month-old APP/PS1
mice. Bonferroni correction of 0.05/36= 0.0014was applied, meaning
P-values less than this value were considered statistically significant
Antibody Group Log N Age (month) Difference
z P




Abbreviations: Aβ, amyloid beta; Aβo, amyloid beta oligomers; Aβp, amyloid
beta plaques.
F IGURE 5 Age-dependent accumulation of amyloid beta (Aβ)
oligomers and Aβ plaques. Quantification of the age dependent
accumulation of cerebral and retinal Aβ oligomers and Aβ plaques with
nanobodies: Immunodetection and quantification of retinal and
cerebral Aβ1-40 and Aβ1-42 with PrioAD12 and PrioAD13 nanobodies
in the cerebral cortex and hippocampus and retina of 3- to
4-month-old (n= 8) and 17- to 18-month-old (n= 8) APP/PS1mice
using cellSens software image analysis after immunohistochemical
staining. Total Aβ plaque burden (Aβp) was quantified in the cerebral
cortex and hippocampus and retina of 3- to 4-month-old (n= 8) and
17- to 18-month-old (n= 8) APP/PS1mice.Wilcoxon-Mann-Whitney
test was performed and normalized intensity of both Aβ1-40 and Aβ1-42
oligomers were significantly higher in the retina of 3- to 4-month-old
compared to the 17- to 18-month-old age group APP/PS1mice (P=
.0002) whereas Aβp loadwas significantly higher in brain and retina of
the 17- to 18-month-old age group compared to the 3- to 4-month-old
age group (P= .0002). Error bars represent interquartile range
APP/PS1 mice via immunoprecipitation followed by western blotting.
Aβ1-40 and Aβ1-42 oligomer levels were significantly higher compared
to WT mice in the 3-month-old age group, while their levels were ele-
vated for Aβ1-40 oligomers and reduced for Aβ1-42 oligomers in the
18-month-old age group compared to the 3-month-old age group. The
F IGURE 6 Quantification of amyloid beta (Aβ) oligomers in blood.
Quantification of the age-dependent accumulation of blood-borne Aβ
oligomers with nanobodies. Immunodetection and quantification of
blood-borne Aβ1-40 and Aβ1-42 with PrioAD12 and PrioAD13
nanobodies in whole blood of 3- to 4-month-old (n= 8) and 17- to
18-month-old (n= 8) APP/PS1mice using ImageJ software analysis
after western blotting. The normalized intensity was calculated in
three independent experiments for each age group and the final result
was presented asmedian intensity. Paired t-tests were performed and
P-values below .05were considered significant. Levels of both Aβ1–40
and Aβ1–42 oligomers were significantly higher in the 3- to 4-month
age group. Aβ1-40 oligomer level increased significantly from 3 to 4 to
17 to 18months whereas Aβ1-42 oligomer level decreased by at least
three-fold in the 17- to 18-month-old APP/PS1mice. Error bars
represent interquartile range
reduction of Aβ1-42 in the older age groupmirrors the biological behav-
ior of this assembly inhumanAD inwhichplasmaAβ1-42 or totalAβ1-42/
Aβ1-40 ratio is used as a strong predictor of amyloid-PET status.51,52
Although the levels of blood-borne Aβ levels were significantly higher
in APP/PS1 compared to the levels in the WT littermates, the west-
ern blot technique has its limitations and might generally lead to false
positives.53
We have previously shown a strong inverse correlation between
retinal Aβo and brain Aβp deposition.39 This previous study provided
the rationale for assessing and comparing age-dependent accumula-
tion of Aβo in the retina, whole blood, and brain. In this current study,
the 3- to 4-month-old APP/PS1 age group displayed extensive accumu-
lation of Aβo deposits in the ONL, INL, and GCL of the retina, whereas
the brain remained free of Aβo deposition. In addition, Aβ plaqueswere
completely absent in both brain and retina in this age group. Retinal
Aβo deposition was lower with age, and was no longer detected in the
17- to18-month-old age groupusing IHC. In contrast, cerebral Aβowas
first detected at 8 months of age in our APP/PS1 mice and remained
unchanged in 11-month-old mice, but was undetectable in 18-month-
old APP/PS1 mice. Consistent with our previous study,39 retinal Aβp
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F IGURE 7 Co-localization of amyloid beta (Aβ) oligomers and plaques. Immunofluorescence co-localization of cerebral and retinal Aβ
oligomers and Aβ plaques in different APP/PS1 age groups. Cerebral and retinal co-staining with anti-Aβ1-40 (PrioAD12) and anti-Aβ1-42
(PrioAD13) nanobodies (GREEN) and 4G8 antibody (RED) of 3- (A-F), 8- (G-L), 11- (M-R), and 18-month-old (S-X) APP/PS1mice. No distinctive
oligomers co-localized with plaques in the brain cortical region (A, D) and in the hippocampus (B, E). Large number of oligomers found in the (C, F)
retinal ganglion cell layer (GCL), inner nuclear layer (INL), and outer nuclear layer (ONL) but no co-localization observed in the 3-month-old mice
(white arrows). Then Aβ1-40 (G, H) and Aβ1-42 (J, K) oligomers co-localized with plaques in the brain cortical region and hippocampus, respectively,
and in the retinal GCL and INL (I, L) of the 8-month-old mice (white arrows), respectively.With age progression, Aβ1-40 (M, N) and Aβ1-42 (P, Q)
oligomers co-localized with plaques in the brain cortical region and hippocampus, respectively, and in the retinal INL (O, R) of the 11-month-old
mice (white arrows). Finally, in 18-month-old APP/PS1mice, Aβ oligomers co-localized with plaques in the brain cortical region (S, V) and in the
hippocampus (T,W) and also in the retinal GCL, INL, andONL (U, X) of the 18-month-old mice, respectively (white arrows). Representative of all
affectedmice in all age groups
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was first detected in 8- to 11-month-old APP/PS1 and increased in the
18-month age group. The lack of detection of Aβo in older animals sup-
ports the hypothesis of Aβo conversion to plaques as the disease pro-
gresses. This is highly speculative as this “conversion” from oligomers
to plaques has not been demonstrated at amolecular level; however, in
our study, themere fact thatAβoarepresent in the retina andnot in the
brain provides momentum to pursue this diagnostic strategy in vivo.
Taken together, and acknowledging the limitations of the study in rela-
tion to the lack of data related to animal behavior in our current study,
these results suggest that retinal Aβo accumulation precedes its cere-
bral deposition and that its simultaneous presence in the blood at high
levels strongly suggests that retinal Aβo originate from the blood,18,54
albeit a lymphatic and/or a CSF origin cannot be ruled out.55 Of note,
fluorescence assessment also showed presence of cerebral Aβo depo-
sitions forming the dense core of the Aβp plaques in the 18-month age
group. This data strengthens the hypothesis of Haass et al.43 suggest-
ing that Aβ plaquesmight act as a reservoir for Aβ oligomers.
In this study, we established that Aβo could be detected simultane-
ously in the blood and retina of APP/PS1mice before their appearance
in the brain. Aβo neuroinvasion appears to originate from blood before
reaching the retina probably via “leaky” blood–ocular barriers.56 A
study byMorin et al.57 reported that APP is synthesized in retinal gan-
glion cells and transported to the optic nerve in small transport vesi-
cles. It can be speculated that blood-borne Aβo deposition in the retina
might initiate a seeding reaction leading to aggregation and spread
to the brain.38 The ability to detect Aβo concurrently in the blood
and retina using nanobodies that specifically bind Aβ1-40 and Aβ1-42
oligomers before cognitive decline and neuropathology are evident
offers a real possibility to establish a screening platform (retinal imag-
ing ofAβo) and a reference diagnostic testing platform (blood testing of
Aβo).
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